Publication | Open Access

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

Met AmplificationOncogenic AgentMedicinePathologyCancer GenomicsLung AdenocarcinomasMet/alk/ros1 Inhibitor CrizotinibCancer GeneticsOncologyRadiation OncologyLung CancerTumor Biology